Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
<h4>Objective</h4>To investigate the prognostic value of preoperative neoadjuvant therapy (NT) compared to upfront surgery (US) in patients with resectable and borderline resectable pancreatic cancer.<h4>Methods</h4>PubMed, Embase, Web of Science were searched to collect rand...
Main Authors: | Shangtong Liu, Hui Li, Yuhui Xue, Liang Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290888&type=printable |
Similar Items
-
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
by: Jordan M. Cloyd, et al.
Published: (2020-04-01) -
Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
by: Marco Massani, et al.
Published: (2023-01-01) -
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01) -
Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
by: CHEN Zegang, et al.
Published: (2022-09-01) -
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
by: Craig L Slingluff, et al.
Published: (2023-12-01)